Generic Product News (June 2015)

Pharmacy Times, June 2015 Women's Health, Volume 81, Issue 6

Read about the new generic products featured in June.

GAVIS Pharmaceuticals

Compare to: HalfLytely (Braintree Laboratories, Inc)

Indication: GAVIS Pharmaceuticals announces the introduction of GaviLyte-H, the most recent addition to the GaviLyte line of products. This 2-L PEG-3350 with 1 bisacodyl tablet and salts provides an alternative precolonoscopy prep and is now available as a value-branded generic. GaviLyte-H is part of GAVIS Pharmaceuticals’ complete family of generic PEG-3350 products.

Dosage Form: 2-L container, flavor pack, GaviLyte-H powder, and 1 bisacodyl tablet

For More Information: www.gavilyte.com

Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg and 1 mg/5 mcgMarketed by: Glenmark

Compare to: FemHRT (Warner Chilcott)

Indication: Glenmark Generics Inc USA has been granted final Abbreviated New Drug Approval from the FDA for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg and 1 mg/5 mcg. Glenmark will commence distribution of the product immediately. The product is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis in women at significant risk of osteoporosis.

Dosage Form: Tablets: 0.5 mg/2.5 mcg and 1 mg/5 mcg

For More Information: www.glenmarkpharma.com

Argatroban Injection in 0.9% Sodium ChlorideMarketed by: Teva Pharmaceuticals, Inc

Indication: Teva Pharmaceutical Industries Ltd announces the launch of Argatroban Injection in 0.9% sodium chloride, 250 mg/250 mL, for intravenous infusion only. Argatroban Injection is indicated for prophylaxis or treatment of thrombosis in adult patients with heparin- induced thrombocytopenia (HIT). Argatroban Injection is also indicated as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention.

Dosage Form: Intravenous infusion: premixed formulation of 250 mg of argatroban in 250 mL sodium chloride solution; dilution is not required

For More Information: www.tevagenerics.com

Aripiprazole TabletsMarketed by: Teva Pharmaceuticals, Inc

Compare to: Abilify (Otsuka Pharmaceutical Co, Ltd)

Indication: Teva Pharmaceutical Industries Ltd announces the launch of Aripiprazole Tablets, which are indicated for the treatment of schizophrenia in adults and in adolescents (13 to 17 years of age). The product is also indicated for acute treatment of manic and mixed episodes associated with bipolar I disorder, both as monotherapy and as adjunctive therapy to lithium or valproate in adults and in “pediatrics” (10 to 17 years of age).

Dosage Form: Tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.

For More Information: www.tevagenerics.com